Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
-
Published:2021-08
Issue:
Volume:38
Page:101010
-
ISSN:2589-5370
-
Container-title:EClinicalMedicine
-
language:en
-
Short-container-title:EClinicalMedicine
Author:
Guo Wanshen, Duan Kai, Zhang Yuntao, Yuan Zhiming, Zhang Yan-BoORCID, Wang Zejun, Zhao Dongyang, Zhang Huajun, Xie Zhiqiang, Li Xinguo, Peng Cheng, Zhang Wei, Yang Yunkai, Chen Wei, Gao Xiaoxiao, You Wangyang, Wang Xue-Wei, Shi Zhengli, Wang Yanxia, Yang Xu-Qin, Zhang Lianghao, Huang Lili, Wang Qian, Lu Jia, Yang Yong-Li, Guo Jing, Zhou Wei, Wan Xin, Wu Cong, Wang Wenhui, Du Jianhui, Nian Xuanxuan, Li Xing-Hang, Huang Shihe, Shen Shuo, Xia Shengli, Pan AnORCID, Yang Xiaoming
Reference56 articles.
1. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. 2021. https://covid19.who.int/ (accessed June 10, 2021). 2. World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines. 2021. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed June 10, 2021). 3. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine;Keech;N Engl J Med,2020 4. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial;Richmond;Lancet,2021 5. Chang-Monteagudo A., Ochoa-Azze R., Climent-Ruiz Y., et al. A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial. medRxiv 2021; published online Mar 3. http://medrxiv.org/content/early/2021/03/03/2021.02.22.21252091.abstract (preprint).
Cited by
33 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|